AD Biomarkers Study

IRB
CHLA-24-00082
Alzheimer’s Disease (AD) Biomarkers in Children with Neurodevelopmental Disorders

Individuals with Down syndrome are at risk for the development of Alzheimer's disease. This study seeks to explore if neurodegenerative biomarkers of this condition are present in childhood. In addition, this study will explore the possibility of these same biomarkers being present in children with autism spectrum disorder and other neurodevelopmental conditions.

Study Details
Time commitment/Requirements
Total time commitment is 20-30 minutes during two visits. This includes the time to complete a demographic and medical history intake questionnaire (duration: roughly 5 minutes), and the time to perform two blood draws (first draw at a baseline visit, second draw at a follow-up 4-8 months after baseline).
Keywords
alzheimer's disease down syndrome, autism spectrum disorder, biomarkers
Study Type
Longitudinal
Eligibility
Age range is 2-24 years of age.

Additional eligibility requirements by group:

Down syndrome (DS) group: No history of neoplasia (any type) or receipt of chemotherapeutics.

Neurodevelopmental (NDD) control group: No diagnosis of Down syndrome, no history of epilepsy, no neurosurgical intervention, no neoplasia (any type) or receipt of chemotherapeutics, no diagnosis that has been previously linked to the development of dementia or Alzheimer’s disease (e.g., Progeria) or a gene mutation on chromosome 21.

Neurotypical control group: No chronic medical problem, no prior or active neurologic disease, no intellectual disability or learning impairment, no history of neoplasia or prior receipt of chemotherapeutics.
Does this study also recruit healthy volunteers?
Yes
Enrollment Status
Open
Label
Research Contact
Contact Email
dsresearch@chla.usc.edu
Phone
(323) 607-3505